Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 268.21B P/E 20.64 EPS this Y 473.50% Ern Qtrly Grth 68.80%
Income 2.31B Forward P/E 13.76 EPS next Y 15.40% 50D Avg Chg -4.00%
Sales 61.4B PEG 0.23 EPS past 5Y -11.65% 200D Avg Chg -3.00%
Dividend 3.00% Price/Book 5.73 EPS next 5Y 66.74% 52W High Chg -12.00%
Recommedations 1.80 Quick Ratio 0.73 Shares Outstanding 2.53B 52W Low Chg 25.00%
Insider Own 0.05% ROA 10.26% Shares Float 2.53B Beta 0.40
Inst Own 78.81% ROE 5.31% Shares Shorted/Prior 18.75M/19.59M Price 105.70
Gross Margin 74.85% Profit Margin 3.76% Avg. Volume 7,449,562 Target Price 141.42
Oper. Margin 42.47% Earnings Date Jul 30 Volume 10,865,850 Change 0.40%
About Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company, Inc. News
05/17/24 Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness
05/17/24 5 Stocks Powering the Dow ETF Year to Date
05/16/24 Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
05/16/24 Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors
05/16/24 The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
05/15/24 Top Stock Reports for Broadcom, Merck & Airbnb
05/15/24 Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
05/14/24 Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
05/14/24 Merck cancels trial of melanoma treatment due to immune-mediated adverse events
05/13/24 Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
05/13/24 Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
05/10/24 Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
05/10/24 The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
05/09/24 Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
05/09/24 Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
05/09/24 Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
05/08/24 Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
05/08/24 Q1 2024 OPKO Health Inc Earnings Call
05/08/24 Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
05/06/24 Gossamer sells rights to drug it hopes can rival a new Merck therapy
MRK Chatroom

User Image basscat12 Posted - 6 hours ago

$CELH $CFLT $MRK It's Sunday. Take time to be spend with your family and be grateful for the blessings you have received, and for those you will receive for all of your tomorrows!

User Image GemsBot Posted - 1 day ago

8 of 11 $MRK $MSFT $NKE Experienced traders are also using tick, volume, range or price change intervals to suit their own trading profile … see 9/11

User Image Reignrx2 Posted - 1 day ago

$VKTX I have theory we know NASH data coming out soon. MAYBE $MRK or $PFE will announce partnership b4 data comes out?

User Image albiegf13 Posted - 1 day ago

@PhoenixLights @HeyU2001 $MRK has been sponsoring a great deal on many of the 24-hour cable news, providing a lot of revenue for them... I suspect they will have significant influence on what news they will cover... The most important fact we have going for us is the FDA approval... THAT'S HUGE...! It's just a matter of time before the word gets out on this baby, and when it does, LOOK OUT...! "BREAKING NEWS...! A SMALL BIOTECH COMPANY IN CALIFORNIA HAS DISCOVERED A CURE FOR CANCER...!"

User Image Joe_Cool Posted - 1 day ago

$IBRX Serum Institute has already prepared I-BCG for 20 Countries around the world. Not like this is a new product that hasn’t already fixed the $MRK the supply shortage for Anktiva’s co-Drug! This is Huge.

User Image Quantumup Posted - 2 days ago

Capital One initiated $IMMP at an Overweight rating, and a $10 price target: Efti w/ pembro in 1L NSCLC has shown a dramatic improvement in mOS over SoC=pembro/chemo + improvement of OS in HNSCC, and also a synergy w/ chemo in late-line mBC. Capital One conservatively models $4.3B in peak sales in mBC, NSCLC, and HNSCC for efti in 2040: $mrk

User Image Long__Strong Posted - 2 days ago

$GSK $MRK $NVAX Bring some attention to $RMSL FDA clearance expected before end of June. A superior device compared to anything currently available globally. Fed has examined the 510k & only had minor questions in regards to packaging & shelf life. Do some DD & buy a few hundred thousand shares at minimum. A 10x to 15x return incoming. GLTA

User Image Flowdollas Posted - 2 days ago

$NVAX Novavax & Sanofi..the Dream Team 👑💎 $MRK $Gsk https://seekingalpha.com/article/4692559-novavax-inc-nvax-q1-2024-earnings-call-transcript

User Image GSMITH10107 Posted - 2 days ago

$CKPT $IBRX $MRK care to explain????? wonder why $CKPT is trading at 65 million market cap... multibagger IMO with major catalysts anyday.

User Image Youngandhappy Posted - 2 days ago

$MRK $ICU Look@the Merk’s 10 year chart. 📈 The future here is just as BlindinglyBright! Mark this post! Mark it and Park $$$$$$$! 10MB

User Image Okenrav Posted - 2 days ago

@LeLionEtLeRat No. $VKTX drug is better than all others by a very long lead. To develop a subpar drug and hope to sell it against VKTX is money losing business (between subpar "2nd" gen GLP1s and VKTX it will be a choice between VKTX and generics - which are not that much worse than these candidates being put forth). It can be another couple of months, as apparently $MRK has a in-house GLP-1 they're testing, till they run out of options. All these BPs need what VKTX has MORE than VKTX needs to sell out.

User Image TalkMarkets Posted - 3 days ago

Which Is The Best Investment For You? High Yield #Pfizer Or Higher Growth #Merck? $MRK $PFE https://talkmarkets.com/content/stocks--equities/which-is-the-best-investment-for-you-high-yield-pfizer-or-higher-growth-merck?post=445998

User Image taxplanr Posted - 3 days ago

$BNTX $MRNA $PFE $MRK Any cyborg bulls want to guess where aminocyanines come from? 🤣 🤣 🤣 It's the blue in Blueberries

User Image FASTgraphs Posted - 3 days ago

Which Is The Best Investment For You? High Yield Pfizer or Higher Growth Merck? | FAST Graphs $MRK $PFE #pfizer #merck #dividends #investing #stocks #stockmarket https://youtu.be/5WvNwgeUtvE?si=m9Pxwi2RomLggQJ-

User Image wealthwithstocks Posted - 3 days ago

$MRK Going for that new high on ultra-solid fundamentals. https://app.ziggma.com/securities/MRK

User Image 100dollars Posted - 3 days ago

$IBRX $MRK $AZN $NVS $BMY come to mama

User Image scalpemfast Posted - 3 days ago

$MRK

User Image 100dollars Posted - 3 days ago

$IBRX who will be the sole owner of this $MRK 131 $AZN 77 $NVS 103 $BMY 44

User Image burningmoneyagain Posted - 3 days ago

$MRK Nice move...

User Image Tryingtofigureitout Posted - 3 days ago

Plays this week, trying to get ~10% a trade but letting a few ride. Still missed out on massive +400% gains (Merck, Lyft, amc) but a profit is a profit. fomo blows up accounts. great returns and keeping my strategy. $MRK 05/17 129c: $0.61 -> .89 $LYFT 05/17 7c: $.18 -> .26 $AMC 05/17 4c: $.73 -> .81 $KR 05/17 55c $.26 -> .32 $BAC 05/17 39p $.25 -> $.28

User Image Wolf77kesh Posted - 3 days ago

$MRK you all think MRK will attempt to buy IBRX with the new drug approval?🤔

User Image ApexSeidon Posted - 3 days ago

Ok so the only news I see about $VKTX is two firms increasing their position according to their 13F -Avoro Capita- 3.43% increase -Perceptive Advisors 1.41% Increase in stake Hearing things about $MRK positive comments as well but not sure if that's 100% true. Will have to confirm on that

User Image Okenrav Posted - 3 days ago

@Jackie_O_ Yes. $MRK goes to $200 with this.

User Image Okenrav Posted - 4 days ago

$VKTX if $MRK is buying this, why is $PFE going up? Buy back? Bottomless well of crookery!

User Image kellyCriterion101 Posted - 4 days ago

$VKTX “the asset is good!” - MERCK MANAGEMENT AT A CONFERENCE 30 MIN AGO $MRK

User Image taxplanr Posted - 4 days ago

$MRNA $BNTX $PFE $MRK the Cancer industry will probably end up being just add Ivermectin and/or Fenbendazole for safe effective cancer treatments

User Image Teleboy Posted - 4 days ago

$AIM It has been a couple of weeks so here's an update: Excellent interim data from both the combo $AZN Pancreatic trial and the combo $MRK UPitt recurrent Ovarian; other positive updates from TNBC, Melanoma, and the Dutch trial's Pancreatic dosing safety data. Also a large batch of Ampligen was manufactured. Conference call May 16 at 0830 Awaiting news on the following: 1. Detailed UPitt ovarian cancer data update due Q2 NCT03734692 (phase 1 and 2) 2. Takeover/licensing negotiations progress. 3. TNBC final trial results with Keytruda and Celebrex $PFE NCT03599453 (phase 1) 4. Pancreatic cancer trial updates 5. Detailed Long-Covid Trial data

User Image Diefreeandsell Posted - 4 days ago

@chrundel last one i was in was $RXDX bought by $MRK. same story held up by granite or $GS who handled transaction.

User Image cb5000calls Posted - 4 days ago

$SLS and just look at the zoomed in monthly and you can see the mass accumulation that all started to perk up in October of 2023 when they faked retail out with the RS threat only to rocket it back to $1.50 fast so tutes could load $20 million worth. October was the same time we got great data on $MRK combo for GPS, same time we got FDA fast track and Orhan from FDA for SLS009, Same time we got positive phase 2a on SLS009, same time National Cancer institute started running joint studies... all of which was shorted to trick retail in folding after a 2/3 year short manipulation play with zero capitulation event. Market cap is 10x more manipulated than $GME and $AMC relative to float size, and the shorts are about to get exposed very soon.

User Image sister Posted - 5 days ago

$PFE gets cheaper on this $AMGN news . . . much cheaper. $MRK $BMY $LLY

Analyst Ratings
Truist Securities Buy Apr 26, 24
Cantor Fitzgerald Overweight Apr 18, 24
Berenberg Buy Apr 8, 24
Cantor Fitzgerald Overweight Apr 5, 24
Cantor Fitzgerald Overweight Apr 1, 24
Truist Securities Buy Mar 28, 24
Cantor Fitzgerald Overweight Mar 27, 24
Wells Fargo Equal-Weight Mar 27, 24
Societe Generale Sell Mar 11, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 102.3841 2,081 213,061 18,191 11/13/23
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Nov 08 Sell 105.0286 43,823 4,602,668 111,764 11/09/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Oct 30 Option 102.82 915 94,080 20,723 10/31/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Sell 114.93 143,329 16,472,802 271,817 04/28/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Option 56.04 143,329 8,032,157 415,146 04/28/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Sell 115.07 134,055 15,425,709 04/14/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Option 59.06 134,055 7,917,288 134,055 04/14/23
Romanelli Joseph President, Human Hea.. President, Human Health Int?l Feb 15 Sell 108.2201 5,000 541,100 20,284 02/16/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 13 Sell 109.1003 1,815 198,017 33,085 02/14/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 09 Sell 107.0013 5,000 535,006 34,900 02/10/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 06 Sell 104.2546 4,436 462,473 39,900 02/08/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 103.21 1,795 185,262 16,731 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Option 0 167,613 415,206 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Sell 102.84 167,613 17,237,321 247,593 11/10/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Option 0 235,769 936,422 11/08/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Sell 99.31 235,769 23,414,219 700,653 11/08/22
Oosthuizen Johannes Jacobus SVP, U.S. Market SVP, U.S. Market May 03 Option 87.1 907 79,000 14,961 05/05/22
Garay Arpa SVP Human Health Glo.. SVP Human Health Global Mktg. May 03 Option 87.1 907 79,000 2,368 05/05/22
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 03 Option 87.1 949 82,658 41,429 05/05/22
Klobuchar Michael A EVP - Chief Strategy.. EVP - Chief Strategy Officer May 03 Option 87.1 885 77,084 15,775 05/05/22
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 03 Option 87.1 813 70,812 3,943 05/05/22
Litchfield Caroline EVP & CFO EVP & CFO May 03 Option 87.65 773 67,753 27,799 05/04/22
Li Dean Y Executive VP & Presi.. Executive VP & President, MRL May 03 Option 87.65 773 67,753 16,839 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer May 03 Option 87.65 427 37,427 9,410 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer Feb 10 Option 76.53 1,202 91,989 7,421 02/14/22
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Option 29.35 42,120 1,236,222 136,857 11/02/21
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Sell 87.87 39,762 3,493,887 97,095 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Option 0 135,405 252,335 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Sell 87.56 135,405 11,856,062 116,930 11/02/21
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 06 Option 75.98 1,212 92,088 36,215 05/06/21
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 06 Option 75.98 694 52,730 2,612 05/06/21
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Nov 03 Option 75.89 4,574 347,121 7,624 11/03/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Option 0 251,273 422,329 10/06/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Sell 81.03 251,273 20,360,651 171,056 10/06/20